+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 18Years +
All Genders
ID06764095

Evaluating Enfortumab Vedotin and Pembrolizumab with Bladder andor Ureter Surgery for Advanced Bladder and Upper Urothelial Tract Cancer

Led by Mayo Clinic · Updated on 2026-10-01

75

Participants Needed

1

Research Sites

182 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effects of standard care treatment combining enfortumab vedotin and pembrolizumab followed by surgical removal of all or part of the bladder cytoreductive cystectomy andor the ureter ureterectomy in patients with locally advanced or metastatic bladder and upper urothelial tract cancer. This phase IV trial aims to assess if this combined approach can improve patient outcomes such as progression-free survival and overall survival. Participants receive enfortumab vedotin intravenously on days 1 and 8, and pembrolizumab intravenously on day 1 of each 3-week cycle, for at least four cycles 12 weeks unless disease progression or unacceptable side effects occur. Those eligible for surgery may undergo cystectomy andor ureterectomy, and may also receive metastasis-directed therapy as needed. After surgery, patients may continue maintenance therapy with the same drugs. Throughout the study, patients will undergo urine and blood sample collections along with imaging scans such as CT, PETCT, or MRI. Participants will be closely monitored with regular follow-ups every 9 weeks for up to 18 months after treatment, then every 12 weeks for up to 5 years. Researchers will evaluate progression-free survival at 12 months as the main outcome, along with overall response rates, surgical candidacy, pathological complete responses, and side effects. Patient-reported quality of life and prognostic biomarkers from blood and urine samples will also be assessed during the study period.

CONDITIONS

Brief Title

Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial

Research Team

C

Clinical Trials Referral Office

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here